<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01634139</url>
  </required_header>
  <id_info>
    <org_study_id>205.445</org_study_id>
    <secondary_id>2011-001758-26</secondary_id>
    <nct_id>NCT01634139</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation
      solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over
      48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent
      asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Peak (0-3h) Change From Baseline</measure>
    <time_frame>Baseline and 24 Weeks.</time_frame>
    <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 24.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from Baseline in Trough (pre-dose) Forced Expiratory Volume (FEV) in 1 second (FEV1) measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Peak (0-3h) at Week 48 Change From Baseline</measure>
    <time_frame>Baseline and Week 48.</time_frame>
    <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC (0-3h) Change From Baseline</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at week 24</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Change From Baseline at Each Individual Timepoint</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
    <description>FEV1 change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Peak(0-3h) Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 24 and 48 Weeks of treatment.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48</time_frame>
    <description>Change from baseline in Trough (pre-dose) FVC measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (0-3h) Change From Baseline</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
    <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Change From Baseline at Each Individual Timepoint</measure>
    <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at Week 24</time_frame>
    <description>FVC change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN (Pro re Nata) Rescue Medication Per Day</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at weeks 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN Rescue Medication During Daytime</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during daytime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of PRN Rescue Medication During Nighttime</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during nighttime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) a.m. Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF p.m. Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Variability Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in the peak expiratory flow variability based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 a.m Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 p.m. Change From Baseline</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ−IA Total Score</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>Interviewer Administered Asthma Control Questionnaire (ACQ-IA) total score after 24 and 48 weeks of treatment.
The ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACQ−IA Responder Analysis</measure>
    <time_frame>Weeks 24 and 48</time_frame>
    <description>Responder categories based on the ACQ-IA total score after 24 and 48 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5). No statistical testing was performed for ACQ-IA total score responders.
The ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAQLQ(S) Total Score</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>Standardised Paediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) total score at weeks 24 and 48.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). Total Score is calculated as mean of all 23 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAQLQ(S) Symptom Domain Score</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>PAQLQ(S) symptom domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score was calculated as the mean of the items in the domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAQLQ(S) Activity Limitation Domain Score</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>PAQLQ(S) activity limitation domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAQLQ(S) Emotional Function Domain Score</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>PAQLQ(S) emotional function domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders in PAQLQ(S) at Weeks 24 and 48</measure>
    <time_frame>Weeks 24 and 48.</time_frame>
    <description>Responders in PAQLQ(S) at weeks 24 and 48. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≥0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≤-0.5). No statistical testing was performed for PAQLQ(S) total score responders.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nighttime Awakenings</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in nighttime awakenings based on the weekly mean at weeks 24 and 48.
Nighttime awakenings was assessed by the question &quot;Did you wake up during the night due to your asthma?&quot; from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Asthma Symptoms</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in morning asthma symptoms based on the weekly mean at weeks 24 and 48.
Morning asthma symptoms was assessed by the question &quot;how were your asthma symptoms this morning?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Asthma Symptoms</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in daytime asthma symptoms based on the weekly mean at weeks 24 and 48.
Daytime asthma symptoms was assessed by the question &quot;how were your asthma symptoms during the day?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Activity Limitations</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in daytime activity limitations based on the weekly mean at weeks 24 and 48.
Daytime activity limitations was assessed by the question &quot;how limited were you in your activities today because of your asthma?&quot; from the e-diary. Scores range from 1 (not limited) to 5 (totally limited).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Experiences of Shortness of Breath</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in daytime experiences of shortness of breath based on the weekly mean at weeks 24 and 48.
Daytime experiences of shortness of breath was assessed by the question &quot;how much shortness of breath did you experience during the day&quot; from the e-diary. Scores range from 1 (none) to 5 (a very great deal).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Experiences of Wheeze or Cough</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at weeks 24 and 48.
Daytime experiences of wheeze or cough was assessed by the question &quot;did you experience wheeze or cough during the day?&quot; from the e-diary. Scores range from 1 (not at all) to 5 (all the time).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Asthma Symptom-free Days</measure>
    <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
    <description>Change from baseline in asthma symptom-free days based on the weekly mean at weeks 24 and 48.
A day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary (electronic diary) and no use of rescue medication reported via the eDiary during that day.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N's for each timepoint display the number of participants with available data at that timepoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tiotropium high dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium low dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium low dose QD</intervention_name>
    <description>2 actuations once daily in the evening</description>
    <arm_group_label>Tiotropium low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium high dose QD</intervention_name>
    <description>2 actuations once daily in the evening</description>
    <arm_group_label>Tiotropium high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 actuations once daily in the evening</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Inclusion criteria are:

          1. All patients' parent(s) (or legal guardian) must sign and date an informed consent
             prior to participation in the trial. In addition, an informed assent suitable for this
             age group has to be obtained from patients. A separate informed consent/assent is
             required for pharmacogenomic sampling.

          2. Male or female patients between 6 and 11 years of age.

          3. All patients must have at least a 6-month history of asthma.

          4. All patients must have been on maintenance treatment with an inhaled corticosteroid at
             a stable medium dose, either as mono treatment or in combination with another
             controller medication, for at least 4 weeks before Visit 1. While the LTRA is
             permitted throughout the trial, the LABA has to be stopped at least 24 hours prior to
             Visit 1, as no LABAs are permitted during screening and treatment period of this
             trial.

          5. All patients must be symptomatic (partly controlled) at Visit 1 and prior to
             randomisation at Visit 2 as defined by an Asthma Control Questionnaire (ACQ-IA) mean
             score &gt;= 1.5.

          6. All patients must have a pre-bronchodilator forced expiratory volume in one second
             (FEV1) &gt;= 60% and =&lt; 90% of predicted normal at Visit 1.

          7. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator, considered as 100%)
             as compared to Visit 2 (pre-dose) must be within ± 30%.

          8. All patients must confirm the diagnosis of asthma by bronchodilator reversibility at
             Visit 1, resulting in an increase in FEV1 of &gt;= 12%, 15 to 30 minutes after 200 mcg
             salbutamol/albuterol.

          9. Patients must be able to use the Respimat inhaler correctly.

         10. Patients must be able to perform all trial related procedures including technically
             acceptable pulmonary function tests and use of electronic diary/peak flow meter (diary
             compliance of at least 80% is required).

        Exclusion criteria:

        Exclusion criteria are:

          1. Patients with a significant disease other than asthma.

          2. Patients with a clinically relevant abnormal haematology or blood chemistry at
             screening.

          3. Patients with a history of congenital or acquired heart disease, or patients who have
             been hospitalized for cardiac syncope or failure during the past year.

          4. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year.

          5. Patients with a malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years.

          6. Patients with known active tuberculosis.

          7. Patients who have undergone thoracotomy with pulmonary resection.

          8. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the six weeks prior to Visit 1.

          9. Patients with known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other
             components of the inhalation solution used with the Respimat inhaler.

         10. Pregnant or nursing female patients, including postmenarchal girl with a positive
             urine pregnancy test at Visit 1.

         11. Postmenarchal girl of child-bearing potential not using a highly effective method of
             birth control.

         12. Patients who have been treated with anti-IgE treatment within the last six months
             prior to Visit 1 and/or during the screening period.

         13. Patients who have been treated with systemic corticosteroids within four weeks prior
             to Visit 1.

         14. Patients who have been treated with systemic beta-adrenergics within four weeks prior
             to Visit 1.

         15. Patients who have been treated with oral beta-blocker medication within four weeks
             prior to Visit 1 and/or during the screening period.

         16. Patients who have been treated with inhaled long-acting anticholinergics or systemic
             anticholinergic treatment within four weeks prior to Visit 1 and/or during the
             screening period or who have been treated with inhaled short-acting anticholinergics
             within two weeks prior to Visit 1.

         17. Patients who have been treated with long-acting theophylline preparations within four
             weeks prior to Visit 1 and/or during the screening period or who have been treated
             with short-acting theophylline preparations within two weeks prior to Visit 1.

         18. Patients who have been treated with non-approved and according to international
             guidelines not recommended experimental drugs for routine asthma therapy within four
             weeks prior to Visit 1 and/or during the screening period.

         19. Patients who have taken an investigational drug within six half lives according to the
             investigator's information, or four weeks (whichever is greater) prior to Visit 1
             and/or during the screening period.

         20. Patients who have previously been randomised in this trial or are currently
             participating in another trial.

         21. Patients with any acute asthma exacerbation or respiratory tract infection in the four
             weeks prior to Visit 1 and /or in four weeks prior to Visit 2. In case of an asthma
             deterioration occurring in the four weeks prior to Visit 1 and/or in the four weeks
             prior to Visit 2, the visit must be postponed.

         22. Patients requiring six or more puffs of rescue medication per day on more than two
             consecutive days in the four weeks prior to Visit 1 and/or in the four weeks prior to
             Visit 2. In case of an asthma deterioration occurring in the four weeks prior to Visit
             1 and/or in the four weeks prior to Visit 2, the visit must be postponed.

         23. Patients who are unable to comply with medication restrictions prior to Visit 1 and or
             Visit 2.

         24. Patients with a known narrow-angle glaucoma, or any other disease where
             anticholinergic treatment is contraindicated.

         25. Patients with moderate to severe renal impairment, as defined by a creatinine
             clearance &lt;50 mL/min/1.73 m2 BSA, as tiotropium is a predominantly renally excreted
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.445.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35901 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35903 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.02003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.02001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ettenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.50201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.50202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.50203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.50204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.50205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ajka</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dombovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guri</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Adazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baldone</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balvi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rezekne</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Utena</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.35105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.70010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kriviy Rig</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.445.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
    <country>Peru</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>June 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2016</results_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="P3">
          <title>Tio R5</title>
          <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): This patient set included all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Respimat</title>
          <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="B2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="B3">
          <title>Tio R5</title>
          <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="135"/>
            <count group_id="B4" value="401"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="1.6"/>
                    <measurement group_id="B2" value="9.0" spread="1.6"/>
                    <measurement group_id="B3" value="8.9" spread="1.7"/>
                    <measurement group_id="B4" value="8.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Peak (0-3h) Change From Baseline</title>
        <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 24.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
        <time_frame>Baseline and 24 Weeks.</time_frame>
        <population>Full Analysis Set (FAS) was equal to treated set which included all randomised patients who received at least 1 documented dose of study medication. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak (0-3h) Change From Baseline</title>
          <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 24.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
          <population>Full Analysis Set (FAS) was equal to treated set which included all randomised patients who received at least 1 documented dose of study medication. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" spread="0.027"/>
                    <measurement group_id="O2" value="0.395" spread="0.026"/>
                    <measurement group_id="O3" value="0.389" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis was performed in a stepwise manner, firstly for this endpoint, then Trough FEV1. Each step was only considered confirmatory if all previous steps were successful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Stepwise testing of the null hypothesis was used to test the efficacy of Tio R5 and then Tio R2.5, each over placebo. The analysis was performed in a stepwise manner, firstly for this endpoint, then Trough FEV1. Each step was only considered confirmatory if all previous steps were successful.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.103</ci_lower_limit>
            <ci_upper_limit>0.255</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Change From Baseline</title>
        <description>Change from Baseline in Trough (pre-dose) Forced Expiratory Volume (FEV) in 1 second (FEV1) measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>Full Analysis Set (FAS) was equal to treated set which included all randomised patients who received at least 1 documented dose of study medication. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Change From Baseline</title>
          <description>Change from Baseline in Trough (pre-dose) Forced Expiratory Volume (FEV) in 1 second (FEV1) measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>Full Analysis Set (FAS) was equal to treated set which included all randomised patients who received at least 1 documented dose of study medication. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.031"/>
                    <measurement group_id="O2" value="0.272" spread="0.030"/>
                    <measurement group_id="O3" value="0.274" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" spread="0.032"/>
                    <measurement group_id="O2" value="0.337" spread="0.030"/>
                    <measurement group_id="O3" value="0.365" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0477</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Peak (0-3h) at Week 48 Change From Baseline</title>
        <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
        <time_frame>Baseline and Week 48.</time_frame>
        <population>FAS. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Peak (0-3h) at Week 48 Change From Baseline</title>
          <description>Change from baseline in peak forced expiratory volume (FEV) in 1 second within the first 3 hours (h) post dosing (FEV1 peak(0-3h)) measured at week 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
          <population>FAS. Missing data at a visit was imputed by available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="130"/>
                <count group_id="O3" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.351" spread="0.027"/>
                    <measurement group_id="O2" value="0.474" spread="0.026"/>
                    <measurement group_id="O3" value="0.477" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.124</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.062</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.065</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at week 24</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FEV1 (FEV1 AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" spread="0.026"/>
                    <measurement group_id="O2" value="0.306" spread="0.025"/>
                    <measurement group_id="O3" value="0.309" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.154</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.095</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Change From Baseline at Each Individual Timepoint</title>
        <description>FEV1 change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Change From Baseline at Each Individual Timepoint</title>
          <description>FEV1 change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes pre-dose (Week 24) (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.031"/>
                    <measurement group_id="O2" value="0.272" spread="0.030"/>
                    <measurement group_id="O3" value="0.274" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose (Week 24) (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.027"/>
                    <measurement group_id="O2" value="0.295" spread="0.026"/>
                    <measurement group_id="O3" value="0.307" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Week 24) (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165" spread="0.028"/>
                    <measurement group_id="O2" value="0.313" spread="0.027"/>
                    <measurement group_id="O3" value="0.312" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Week 24) (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" spread="0.028"/>
                    <measurement group_id="O2" value="0.307" spread="0.027"/>
                    <measurement group_id="O3" value="0.312" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose (Week 24) (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.147" spread="0.027"/>
                    <measurement group_id="O2" value="0.325" spread="0.026"/>
                    <measurement group_id="O3" value="0.322" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>10 minutes pre-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>10 minutes pre-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>30 minutes post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.151</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.088</ci_lower_limit>
            <ci_upper_limit>0.213</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1 hour post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.148</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.211</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 hours post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.226</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.168</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>3 hours post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.240</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Peak(0-3h) Change From Baseline</title>
        <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 24 and 48 Weeks of treatment.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Peak(0-3h) Change From Baseline</title>
          <description>Change from baseline in Maximum forced vital capacity (FVC) measured within the first 3 hours after administration of trial medication (FVC peak(0-3h)) after 24 and 48 Weeks of treatment.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=124, 130, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.215" spread="0.033"/>
                    <measurement group_id="O2" value="0.325" spread="0.032"/>
                    <measurement group_id="O3" value="0.307" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.361" spread="0.033"/>
                    <measurement group_id="O2" value="0.430" spread="0.032"/>
                    <measurement group_id="O3" value="0.413" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.184</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.165</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0687</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1666</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Change From Baseline</title>
        <description>Change from baseline in Trough (pre-dose) FVC measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Change From Baseline</title>
          <description>Change from baseline in Trough (pre-dose) FVC measured at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.035"/>
                    <measurement group_id="O2" value="0.246" spread="0.034"/>
                    <measurement group_id="O3" value="0.206" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" spread="0.035"/>
                    <measurement group_id="O2" value="0.341" spread="0.034"/>
                    <measurement group_id="O3" value="0.333" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1980</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1256</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1880</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC (0-3h) Change From Baseline</title>
        <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at 24 weeks</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC (0-3h) Change From Baseline</title>
          <description>Change from baseline of area under the curve (AUC) from 0 to 3 hours for FVC (Forced vital capacity) (FVC AUC (0-3h)) after 24 weeks of treatment. The AUC was calculated by using the trapezoidal rule divided by the observation time (3h).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants with available data at the timepoint of interest.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" spread="0.030"/>
                    <measurement group_id="O2" value="0.235" spread="0.029"/>
                    <measurement group_id="O3" value="0.207" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.143</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Change From Baseline at Each Individual Timepoint</title>
        <description>FVC change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and 10 mins before drug administration and 30 mins, 1 hour (h), 2h, 3h after drug administration at Week 24</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Change From Baseline at Each Individual Timepoint</title>
          <description>FVC change from baseline to week 24 at each individual timepoint.
The measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 minutes pre-dose (Week 24) (N=124, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.154" spread="0.035"/>
                    <measurement group_id="O2" value="0.246" spread="0.034"/>
                    <measurement group_id="O3" value="0.206" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose (Week 24) (N=124, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.144" spread="0.032"/>
                    <measurement group_id="O2" value="0.222" spread="0.031"/>
                    <measurement group_id="O3" value="0.211" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour post-dose (Week 24) (N=124, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.032"/>
                    <measurement group_id="O2" value="0.252" spread="0.031"/>
                    <measurement group_id="O3" value="0.202" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose (Week 24) (N=124, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.033"/>
                    <measurement group_id="O2" value="0.230" spread="0.031"/>
                    <measurement group_id="O3" value="0.210" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours post-dose (Week 24) (N=124, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.033"/>
                    <measurement group_id="O2" value="0.233" spread="0.032"/>
                    <measurement group_id="O3" value="0.210" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>10 minutes pre-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0228</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>10 minutes pre-dose.(Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1980</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.052</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>30 minutes post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0344</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.150</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>30 minutes post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0696</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.005</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1 hour post-dose (week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>1 hour post-dose (week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1044</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.060</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 hours post-dose (week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 hours post-dose (week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0130</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.037</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>3 hours post-dose (week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3 hours post-dose (Week 24)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0156</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.092</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN (Pro re Nata) Rescue Medication Per Day</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at weeks 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN (Pro re Nata) Rescue Medication Per Day</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used per day (24 hour period) based on the weekly mean at weeks 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.437" spread="0.079"/>
                    <measurement group_id="O2" value="-0.603" spread="0.077"/>
                    <measurement group_id="O3" value="0.646" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=120, 123, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.484" spread="0.079"/>
                    <measurement group_id="O2" value="0.638" spread="0.078"/>
                    <measurement group_id="O3" value="0.685" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1349</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.165</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.110</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.382</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0588</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.110</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.425</ci_lower_limit>
            <ci_upper_limit>0.008</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1675</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.154</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.111</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.372</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0709</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.201</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.111</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.419</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN Rescue Medication During Daytime</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during daytime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN Rescue Medication During Daytime</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during daytime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.234" spread="0.055"/>
                    <measurement group_id="O2" value="-0.350" spread="0.053"/>
                    <measurement group_id="O3" value="-0.375" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.247" spread="0.055"/>
                    <measurement group_id="O2" value="-0.372" spread="0.053"/>
                    <measurement group_id="O3" value="-0.378" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0749</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.245</ci_lower_limit>
            <ci_upper_limit>0.012</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0305</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.065</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.269</ci_lower_limit>
            <ci_upper_limit>-0.013</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0581</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.125</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.255</ci_lower_limit>
            <ci_upper_limit>0.004</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0464</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.260</ci_lower_limit>
            <ci_upper_limit>-0.002</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of PRN Rescue Medication During Nighttime</title>
        <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during nighttime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of PRN Rescue Medication During Nighttime</title>
          <description>Change from baseline in the number of puffs of rescue medication (salbutamol/albuterol) used during nighttime based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Number of puffs of rescue medication</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.178" spread="0.051"/>
                    <measurement group_id="O2" value="-0.274" spread="0.050"/>
                    <measurement group_id="O3" value="-0.304" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 122, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.198" spread="0.052"/>
                    <measurement group_id="O2" value="-0.298" spread="0.050"/>
                    <measurement group_id="O3" value="-0.301" spread="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1182</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.217</ci_lower_limit>
            <ci_upper_limit>0.025</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0404</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.061</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.246</ci_lower_limit>
            <ci_upper_limit>-0.006</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1105</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.221</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0983</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.062</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.224</ci_lower_limit>
            <ci_upper_limit>0.019</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) a.m. Change From Baseline</title>
        <description>Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) a.m. Change From Baseline</title>
          <description>Change from baseline in the morning (a.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres per min (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.153" spread="4.556"/>
                    <measurement group_id="O2" value="22.660" spread="4.406"/>
                    <measurement group_id="O3" value="21.646" spread="4.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 122, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.824" spread="4.581"/>
                    <measurement group_id="O2" value="26.362" spread="4.440"/>
                    <measurement group_id="O3" value="29.598" spread="4.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1146</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.507</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.387</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.063</ci_lower_limit>
            <ci_upper_limit>19.077</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1628</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.493</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.365</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.034</ci_lower_limit>
            <ci_upper_limit>18.020</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3085</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.538</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.435</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.127</ci_lower_limit>
            <ci_upper_limit>16.203</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1053</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.774</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.413</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.847</ci_lower_limit>
            <ci_upper_limit>19.394</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF p.m. Change From Baseline</title>
        <description>Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF p.m. Change From Baseline</title>
          <description>Change from baseline in the evening (p.m.) peak expiratory flow based on the weekly mean at weeks 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres per min (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N= 121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.179" spread="4.597"/>
                    <measurement group_id="O2" value="15.539" spread="4.444"/>
                    <measurement group_id="O3" value="17.325" spread="4.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.100" spread="4.622"/>
                    <measurement group_id="O2" value="15.219" spread="4.475"/>
                    <measurement group_id="O3" value="21.276" spread="4.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0236</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>12.360</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.451</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.663</ci_lower_limit>
            <ci_upper_limit>23.056</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.427</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.497</ci_lower_limit>
            <ci_upper_limit>24.794</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7322</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.882</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.497</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.667</ci_lower_limit>
            <ci_upper_limit>8.904</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4463</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.481</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.578</ci_lower_limit>
            <ci_upper_limit>14.929</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Variability Change From Baseline</title>
        <description>Change from baseline in the peak expiratory flow variability based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Variability Change From Baseline</title>
          <description>Change from baseline in the peak expiratory flow variability based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Percentage of PEF</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 129, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.204" spread="0.826"/>
                    <measurement group_id="O2" value="-0.942" spread="0.798"/>
                    <measurement group_id="O3" value="-1.038" spread="0.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=117, 120, 121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.320" spread="0.835"/>
                    <measurement group_id="O2" value="-0.048" spread="0.814"/>
                    <measurement group_id="O3" value="-0.899" spread="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.262</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.775</ci_lower_limit>
            <ci_upper_limit>2.299</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8731</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.875</ci_lower_limit>
            <ci_upper_limit>2.208</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7975</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.272</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.058</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.803</ci_lower_limit>
            <ci_upper_limit>2.346</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5845</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.579</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.656</ci_lower_limit>
            <ci_upper_limit>1.498</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 a.m Change From Baseline</title>
        <description>Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 a.m Change From Baseline</title>
          <description>Change from baseline in morning (a.m.) FEV1 based on the weekly mean at week 24 and 48.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.191" spread="0.041"/>
                    <measurement group_id="O2" value="0.209" spread="0.039"/>
                    <measurement group_id="O3" value="0.126" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 122, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.236" spread="0.041"/>
                    <measurement group_id="O2" value="0.259" spread="0.040"/>
                    <measurement group_id="O3" value="0.221" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6932</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1741</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.158</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6250</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.071</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7597</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.048</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.109</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 p.m. Change From Baseline</title>
        <description>Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 p.m. Change From Baseline</title>
          <description>Change from baseline in evening (p.m.) FEV1 based on the weekly mean at week 24 and 48.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Litres (L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 129, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.042"/>
                    <measurement group_id="O2" value="0.142" spread="0.041"/>
                    <measurement group_id="O3" value="0.092" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" spread="0.042"/>
                    <measurement group_id="O2" value="0.208" spread="0.041"/>
                    <measurement group_id="O3" value="0.159" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6166</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.025</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1267</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.173</ci_lower_limit>
            <ci_upper_limit>0.021</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9000</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3897</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.141</ci_lower_limit>
            <ci_upper_limit>0.055</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACQ−IA Total Score</title>
        <description>Interviewer Administered Asthma Control Questionnaire (ACQ-IA) total score after 24 and 48 weeks of treatment.
The ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>ACQ−IA Total Score</title>
          <description>Interviewer Administered Asthma Control Questionnaire (ACQ-IA) total score after 24 and 48 weeks of treatment.
The ACQ-IA is a scale containing 7 questions. Each question has a 7 point scale which ranges from 0 to 6. A score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment. ACQ-IA total score is calculated as the mean of the responses to all 7 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.062"/>
                    <measurement group_id="O2" value="0.897" spread="0.060"/>
                    <measurement group_id="O3" value="0.835" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.817" spread="0.062"/>
                    <measurement group_id="O2" value="0.752" spread="0.060"/>
                    <measurement group_id="O3" value="0.723" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0975</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.262</ci_lower_limit>
            <ci_upper_limit>0.022</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.182</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.323</ci_lower_limit>
            <ci_upper_limit>-0.041</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3732</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.073</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.208</ci_lower_limit>
            <ci_upper_limit>0.078</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1985</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.073</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.236</ci_lower_limit>
            <ci_upper_limit>0.049</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACQ−IA Responder Analysis</title>
        <description>Responder categories based on the ACQ-IA total score after 24 and 48 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5). No statistical testing was performed for ACQ-IA total score responders.
The ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
        <time_frame>Weeks 24 and 48</time_frame>
        <population>FAS, missing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>ACQ−IA Responder Analysis</title>
          <description>Responder categories based on the ACQ-IA total score after 24 and 48 weeks of treatment. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≤-0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≥0.5). No statistical testing was performed for ACQ-IA total score responders.
The ACQ-IA is a scale containing 7 questions, each question has a 7-point scale which ranges from 0 to 6; a score of 0 corresponds to no impairment and a score of 6 corresponds to maximum impairment.</description>
          <population>FAS, missing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responder at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="118"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAQLQ(S) Total Score</title>
        <description>Standardised Paediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) total score at weeks 24 and 48.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). Total Score is calculated as mean of all 23 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PAQLQ(S) Total Score</title>
          <description>Standardised Paediatric Asthma Quality of Life Questionnaire (PAQLQ(S)) total score at weeks 24 and 48.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). Total Score is calculated as mean of all 23 questions.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N= 126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.966" spread="0.065"/>
                    <measurement group_id="O2" value="6.142" spread="0.063"/>
                    <measurement group_id="O3" value="6.093" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.309" spread="0.065"/>
                    <measurement group_id="O2" value="6.288" spread="0.063"/>
                    <measurement group_id="O3" value="6.327" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.316</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0747</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.071</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.267</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7654</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.163</ci_lower_limit>
            <ci_upper_limit>0.120</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8082</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.072</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.124</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAQLQ(S) Symptom Domain Score</title>
        <description>PAQLQ(S) symptom domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score was calculated as the mean of the items in the domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PAQLQ(S) Symptom Domain Score</title>
          <description>PAQLQ(S) symptom domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score was calculated as the mean of the items in the domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.840" spread="0.076"/>
                    <measurement group_id="O2" value="6.015" spread="0.074"/>
                    <measurement group_id="O3" value="5.967" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.195" spread="0.076"/>
                    <measurement group_id="O2" value="6.177" spread="0.074"/>
                    <measurement group_id="O3" value="6.199" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0392</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.175</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.085</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.341</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1351</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.084</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.292</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8291</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.085</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.185</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9655</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.085</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.163</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAQLQ(S) Activity Limitation Domain Score</title>
        <description>PAQLQ(S) activity limitation domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PAQLQ(S) Activity Limitation Domain Score</title>
          <description>PAQLQ(S) activity limitation domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N= 126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.898" spread="0.069"/>
                    <measurement group_id="O2" value="6.089" spread="0.067"/>
                    <measurement group_id="O3" value="6.023" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.249" spread="0.070"/>
                    <measurement group_id="O2" value="6.284" spread="0.068"/>
                    <measurement group_id="O3" value="6.319" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0139</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.191</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.343</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1043</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.125</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.276</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6547</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.078</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.118</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3648</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.077</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.082</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PAQLQ(S) Emotional Function Domain Score</title>
        <description>PAQLQ(S) emotional function domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>PAQLQ(S) Emotional Function Domain Score</title>
          <description>PAQLQ(S) emotional function domain score at weeks 24 and 48. The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control). The individual domain score is calculated as the mean of the items in this domain.
The measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=126, 131, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.157" spread="0.067"/>
                    <measurement group_id="O2" value="6.323" spread="0.065"/>
                    <measurement group_id="O3" value="6.298" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=124, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.481" spread="0.067"/>
                    <measurement group_id="O2" value="6.420" spread="0.065"/>
                    <measurement group_id="O3" value="6.491" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0256</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.312</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0561</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.286</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4127</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.075</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.208</ci_lower_limit>
            <ci_upper_limit>0.085</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8922</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.074</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responders in PAQLQ(S) at Weeks 24 and 48</title>
        <description>Responders in PAQLQ(S) at weeks 24 and 48. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≥0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≤-0.5). No statistical testing was performed for PAQLQ(S) total score responders.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control).</description>
        <time_frame>Weeks 24 and 48.</time_frame>
        <population>FAS, missing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Responders in PAQLQ(S) at Weeks 24 and 48</title>
          <description>Responders in PAQLQ(S) at weeks 24 and 48. Analysis was performed using the following categories and definitions: responder (change from trial baseline ≥0.5), no change (-0.5 &lt;change from trial baseline &lt;0.5) and worsening (change from trial baseline ≤-0.5). No statistical testing was performed for PAQLQ(S) total score responders.
The PAQLQ(S) is 23 questions on a 7-point scale, ranging from 1 (worst control) to 7 (best control).</description>
          <population>FAS, missing data for patients not withdrawn from the study were either categorised as no change or based on available data, withdrawn patients were imputed based upon discontinuation reason.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="96"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsening at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nighttime Awakenings</title>
        <description>Change from baseline in nighttime awakenings based on the weekly mean at weeks 24 and 48.
Nighttime awakenings was assessed by the question &quot;Did you wake up during the night due to your asthma?&quot; from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime Awakenings</title>
          <description>Change from baseline in nighttime awakenings based on the weekly mean at weeks 24 and 48.
Nighttime awakenings was assessed by the question &quot;Did you wake up during the night due to your asthma?&quot; from the e-diary. Scores range from 1 (did not wake up) to 5 (was awake all night).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.070" spread="0.030"/>
                    <measurement group_id="O2" value="-0.079" spread="0.029"/>
                    <measurement group_id="O3" value="-0.144" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 122, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.101" spread="0.030"/>
                    <measurement group_id="O2" value="-0.131" spread="0.029"/>
                    <measurement group_id="O3" value="-0.127" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7931</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.009</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.080</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0369</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.145</ci_lower_limit>
            <ci_upper_limit>-0.005</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4086</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.030</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.101</ci_lower_limit>
            <ci_upper_limit>0.041</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4714</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.097</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Asthma Symptoms</title>
        <description>Change from baseline in morning asthma symptoms based on the weekly mean at weeks 24 and 48.
Morning asthma symptoms was assessed by the question &quot;how were your asthma symptoms this morning?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Asthma Symptoms</title>
          <description>Change from baseline in morning asthma symptoms based on the weekly mean at weeks 24 and 48.
Morning asthma symptoms was assessed by the question &quot;how were your asthma symptoms this morning?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.138" spread="0.039"/>
                    <measurement group_id="O2" value="-0.138" spread="0.038"/>
                    <measurement group_id="O3" value="-0.220" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 122, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.177" spread="0.039"/>
                    <measurement group_id="O2" value="-0.230" spread="0.038"/>
                    <measurement group_id="O3" value="-0.221" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9880</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.091</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0794</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.173</ci_lower_limit>
            <ci_upper_limit>0.010</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2623</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.145</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3552</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.136</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Asthma Symptoms</title>
        <description>Change from baseline in daytime asthma symptoms based on the weekly mean at weeks 24 and 48.
Daytime asthma symptoms was assessed by the question &quot;how were your asthma symptoms during the day?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Asthma Symptoms</title>
          <description>Change from baseline in daytime asthma symptoms based on the weekly mean at weeks 24 and 48.
Daytime asthma symptoms was assessed by the question &quot;how were your asthma symptoms during the day?&quot; from the e-diary. Scores range from 1 (no asthma symptoms) to 5 (very severe asthma symptoms).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.204" spread="0.041"/>
                    <measurement group_id="O2" value="-0.243" spread="0.040"/>
                    <measurement group_id="O3" value="-0.263" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.261" spread="0.042"/>
                    <measurement group_id="O2" value="-0.272" spread="0.041"/>
                    <measurement group_id="O3" value="-0.312" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4359</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.135</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2293</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.155</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8372</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.108</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.148</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Activity Limitations</title>
        <description>Change from baseline in daytime activity limitations based on the weekly mean at weeks 24 and 48.
Daytime activity limitations was assessed by the question &quot;how limited were you in your activities today because of your asthma?&quot; from the e-diary. Scores range from 1 (not limited) to 5 (totally limited).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Activity Limitations</title>
          <description>Change from baseline in daytime activity limitations based on the weekly mean at weeks 24 and 48.
Daytime activity limitations was assessed by the question &quot;how limited were you in your activities today because of your asthma?&quot; from the e-diary. Scores range from 1 (not limited) to 5 (totally limited).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.181" spread="0.039"/>
                    <measurement group_id="O2" value="-0.212" spread="0.038"/>
                    <measurement group_id="O3" value="-0.240" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.227" spread="0.039"/>
                    <measurement group_id="O2" value="-0.238" spread="0.038"/>
                    <measurement group_id="O3" value="-0.259" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1982</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.149</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8019</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.103</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4872</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.123</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Experiences of Shortness of Breath</title>
        <description>Change from baseline in daytime experiences of shortness of breath based on the weekly mean at weeks 24 and 48.
Daytime experiences of shortness of breath was assessed by the question &quot;how much shortness of breath did you experience during the day&quot; from the e-diary. Scores range from 1 (none) to 5 (a very great deal).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Experiences of Shortness of Breath</title>
          <description>Change from baseline in daytime experiences of shortness of breath based on the weekly mean at weeks 24 and 48.
Daytime experiences of shortness of breath was assessed by the question &quot;how much shortness of breath did you experience during the day&quot; from the e-diary. Scores range from 1 (none) to 5 (a very great deal).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.134" spread="0.039"/>
                    <measurement group_id="O2" value="-0.178" spread="0.038"/>
                    <measurement group_id="O3" value="-0.240" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.219" spread="0.039"/>
                    <measurement group_id="O2" value="-0.231" spread="0.038"/>
                    <measurement group_id="O3" value="-0.253" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3498</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.135</ci_lower_limit>
            <ci_upper_limit>0.048</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0222</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.046</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.196</ci_lower_limit>
            <ci_upper_limit>-0.015</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7990</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4586</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.126</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Experiences of Wheeze or Cough</title>
        <description>Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at weeks 24 and 48.
Daytime experiences of wheeze or cough was assessed by the question &quot;did you experience wheeze or cough during the day?&quot; from the e-diary. Scores range from 1 (not at all) to 5 (all the time).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Experiences of Wheeze or Cough</title>
          <description>Change from baseline in daytime experiences of wheeze or cough based on the weekly mean at weeks 24 and 48.
Daytime experiences of wheeze or cough was assessed by the question &quot;did you experience wheeze or cough during the day?&quot; from the e-diary. Scores range from 1 (not at all) to 5 (all the time).
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=121, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.261" spread="0.046"/>
                    <measurement group_id="O2" value="-0.307" spread="0.045"/>
                    <measurement group_id="O3" value="-0.355" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, 123, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.340" spread="0.047"/>
                    <measurement group_id="O2" value="-0.337" spread="0.045"/>
                    <measurement group_id="O3" value="-0.393" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4221</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.156</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0959</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.056</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.204</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9627</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.109</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3457</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.054</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.057</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.165</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Asthma Symptom-free Days</title>
        <description>Change from baseline in asthma symptom-free days based on the weekly mean at weeks 24 and 48.
A day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary (electronic diary) and no use of rescue medication reported via the eDiary during that day.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
        <time_frame>Baseline and Week 24, Baseline and Week 48.</time_frame>
        <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Respimat</title>
            <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Asthma Symptom-free Days</title>
          <description>Change from baseline in asthma symptom-free days based on the weekly mean at weeks 24 and 48.
A day was considered as an asthma symptom-free day if there were no symptoms reported via the e-Diary (electronic diary) and no use of rescue medication reported via the eDiary during that day.
Measured values presented are actually adjusted means.
The number of participants analysed displays the number of participants included in the statistical model whereas the N’s for each timepoint display the number of participants with available data at that timepoint.</description>
          <population>FAS, missing data at a visit was imputed by the available data from the patient at that visit. Completely missing data were handled by the statistical model.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24 (N=122, 130, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135" spread="0.036"/>
                    <measurement group_id="O2" value="0.176" spread="0.034"/>
                    <measurement group_id="O3" value="0.172" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=120, 123, 127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.036"/>
                    <measurement group_id="O2" value="0.170" spread="0.035"/>
                    <measurement group_id="O3" value="0.180" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3375</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.043</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3880</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6541</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.066</ci_lower_limit>
            <ci_upper_limit>0.104</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R2.5 minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 48</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5089</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Repeated measures restricted maximum likelihood model</method_desc>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
            <estimate_desc>Difference calculated as Tio R5 minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug intake until 30 days after last drug intake, up to day 407.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Inhalation of placebo solution (2 puffs) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="E2">
          <title>Tio R2.5</title>
          <description>Inhalation of 2.5mcg tiotropium (Tio R2.5) solution (2 puffs of 1.25mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
        <group group_id="E3">
          <title>Tio R5</title>
          <description>Inhalation of 5mcg tiotropium (Tio R5) solution (2 puffs of 2.5mcg) once daily for 48 weeks delivered by the Respimat inhaler, as add on therapy on top of usual care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Paranasal sinus haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Peak expiratory flow rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

